MOLOGENâ€™S lead products are MGN1703 and MGN1601. MGN1703 is a DNA-based cancer immuno-therapy with an outstanding safety profile. The drug is currently being investigated in a clinical trial phase II/III for the treatment of metastatic colorectal cancer. MGN1601 is a cancer vaccine against renal cell caner. In a clinical phase I/II trial the drug demonstrated a very good tolerability and showed first efficacy.